DDInter1860 DDInter424
Withdrawn in the United Kingdom due to risk of psychiatric adverse drug reactions. This drug continues to be available in the U.S. Internationally, triazolam is a Schedule IV drug under the Convention on Psychotropic Substances.
Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic exposure of coadministered agents that are metabolized by CYP3A enzymes. More specifically, cobicistat is indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection. Increasing systemic exposure of anti-retrovirals (ARVs) without increasing dosage allows for better treatment outcomes and a decreased side effect profile.
Triazolam {u} (Compound) resembles {v} (Compound) Alprazolam
Alprazolam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cobicistat
Triazolam {u} (Compound) resembles {v} (Compound) Midazolam
Midazolam {u} may lead to a major life threatening interaction when taken with {v} Cobicistat
Triazolam {u} (Compound) resembles {v} (Compound) Alprazolam
Alprazolam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bexarotene
Bexarotene {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cobicistat
Triazolam {u} (Compound) resembles {v} (Compound) Flurazepam
Flurazepam {u} (Compound) resembles {v} (Compound) Alprazolam
Alprazolam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cobicistat
Triazolam {u} (Compound) resembles {v} (Compound) Camazepam
Camazepam {u} (Compound) resembles {v} (Compound) Flurazepam
Flurazepam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cobicistat
Triazolam {u} (Compound) resembles {v} (Compound) Alprazolam
Alprazolam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aprepitant
Aprepitant {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cobicistat
Triazolam {u} (Compound) resembles {v} (Compound) Flurazepam
Flurazepam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Imatinib
Imatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cobicistat
Triazolam {u} (Compound) resembles {v} (Compound) Midazolam
Midazolam {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vemurafenib
Vemurafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cobicistat
Triazolam {u} (Compound) resembles {v} (Compound) Camazepam
Camazepam {u} (Compound) resembles {v} (Compound) Midazolam
Midazolam {u} may lead to a major life threatening interaction when taken with {v} Cobicistat
Triazolam {u} (Compound) resembles {v} (Compound) Flunitrazepam
Flunitrazepam {u} (Compound) resembles {v} (Compound) Midazolam
Midazolam {u} may lead to a major life threatening interaction when taken with {v} Cobicistat
Triazolam (Compound) resembles Alprazolam (Compound) and Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Triazolam (Compound) resembles Midazolam (Compound) and Midazolam may lead to a major life threatening interaction when taken with Cobicistat
Triazolam (Compound) resembles Alprazolam (Compound) and Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Triazolam (Compound) resembles Flurazepam (Compound) and Flurazepam (Compound) resembles Alprazolam (Compound) and Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Triazolam (Compound) resembles Camazepam (Compound) and Camazepam (Compound) resembles Flurazepam (Compound) and Flurazepam may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Triazolam (Compound) resembles Alprazolam (Compound) and Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Triazolam (Compound) resembles Flurazepam (Compound) and Flurazepam may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Triazolam (Compound) resembles Midazolam (Compound) and Midazolam may cause a minor interaction that can limit clinical effects when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Triazolam (Compound) resembles Camazepam (Compound) and Camazepam (Compound) resembles Midazolam (Compound) and Midazolam may lead to a major life threatening interaction when taken with Cobicistat
Triazolam (Compound) resembles Flunitrazepam (Compound) and Flunitrazepam (Compound) resembles Midazolam (Compound) and Midazolam may lead to a major life threatening interaction when taken with Cobicistat